Acceleron Pharma’s ACE-536 Corrects Anemia and Iron Overload in Preclinical Model of Beta-Thalassemia

Published: Oct 25, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented data today at the 3rd Pan-European Conference on Hemoglobinopathies and Rare Anemias in Limassol, Cyprus, demonstrating positive effects of ACE-536 to treat both the severe anemia and serious organ damage due to iron overload in a preclinical model of beta-thalassemia. Acceleron is developing ACE-536 in collaboration with Celgene.

Back to news